©LSOphoto via Canva.com
Asthma Inhaler Switch Will Affect Millions Beginning in January
December 29, 2023
The asthma inhaler Flovent, made by GSK, will disappear from pharmacy shelves beginning in January. A generic version will replace Flovent. However, doctors have expressed concern that patients who rely on the medication may experience delays in switching to other medical alternatives and getting them covered by insurance as the new year begins.
The potential for disruption in care is causing distress among users of the drug. However, physicians who treat patients with asthma say the authorized generic will work just as well as the branded drug.
Thank you @megtirrell and @CNN for putting #asthma and the #Flovent discontinuation in the spotlight 🙏 https://t.co/mN5fJcgRT3
— Robyn Cohen MD,MPH (@RobynCohenMD) December 28, 2023
The primary issue concerning users of the drug is that the generic version may be covered less widely than Flovent. CNN quoted Dr. Robyn Cohen, a pediatric pulmonologist at Boston Medical Center, who calls Flovent the go-to drug when treating those with asthma.
“This medication has been the most commonly used inhaled medication for the past 25 or 30 years,” said Cohen. “It’s the one that, overwhelmingly, pediatricians reach for when they decide that their patient needs a daily preventive medication. The fact that it’s being discontinued is going to be a huge shock to the system for patients, for families and for doctors.”
A spokeswoman for GSK said the company introduced generics of Flovent HFA, an inhalation aerosol, in May 2022 and Flovent Diskus, an inhalation powder, in October 2023. Plans to phase out the branded versions of certain inhalers begin Jan. 1, 2024.
The spokeswoman said that the authorized generics “will provide patients in the US with potentially lower cost alternatives of these medically important products.” A provision in the 2021 American Rescue Plan states that starting Jan. 1, 2024, drugs that have been subject to significant price increases over time could end up incurring rebates to Medicaid that are greater than their price. Doctors are urging patients to get new prescriptions if needed and sort out coverage issues as soon as possible.
Recent News
Walgreens Settlement: What You Need to Know
Walgreens recently settled a class action lawsuit, potentially putting cash in the pockets of Americans who faced job denials due to background checks. The settlement, a result of alleged Fair Credit Reporting Act violations, offers up to $918.28 to affected individuals. While Walgreens didn’t admit fault, it agreed to pay an undisclosed sum.
California Electric Bill Overhaul: What’s Ahead
California’s electricity payment system is getting a makeover. Recently, state regulators greenlit a shift to flat-rate billing, aiming to curb surging energy costs. Under this new scheme, most customers of investor-owned utility companies will face a fixed monthly charge of $24.15, trimming the per-kilowatt-hour usage fee by five to seven cents.
AI Has Mastered the Art of Deception
AI, celebrated for its productivity-boosting capabilities, harbors a deceptive side as revealed by recent research. This unsettling finding underscores the need for heightened awareness and regulatory measures to address the risks posed by AI’s ability to induce false beliefs.
Chinese EVs Navigate Global Markets Amid Rising Trade Tensions
China’s electric vehicle (EV) sector is making strategic moves into offshore markets for increased funding, exemplified by the recent success of Zeekr, a premium EV brand under Geely, which saw its shares surge 34% in the largest US IPO by a Chinese company since 2021.